VIJAY CHANDRU, Ph.D
Co-founder and Chairman
Dr. Vijay Chandru (Ph.D., MIT 1982) is an academic entrepreneur recognized as the 'Technology Pioneer' by the World Economic Forum in 2006. His academic career has spanned over two decades at Purdue University and the Indian Institute of Science. Chandru is the recipient of several awards and honors: Fellow of Indian Academy of Sciences (1996), MCIT Dewang Mehta Award for Innovation in IT (2001), UGC Hari Om Trust award for "Science and Society" (2003), the President's Medal of INFORMS in 2006, distinguished Alumni award by the MIT India Program in 2007, and was recognized as the Biospectrum Biotech Entrepreneur of 2007. Chandru was the elected President (2009-2012) of the Association of Biotech Led Enterprises (ABLE), the apex trade body that represents the Indian biotech industry.
Independent Board Member
Ravi Venkatesan is the former Chairman of Microsoft India and currently a Venture Partner at Unitus Seed Fund which invests in early stage social enterprises. He is the founder and Chairman of Social Venture Partners India, a network of engaged philanthropists addressing social problems through venture philanthropy. Ravi is also a director on the boards of Infosys and AB Volvo and the author of an acclaimed book "Conquering the Chaos: Win in India, Win Everywhere" published by Harvard Business Review. He advises many global companies on their emerging market strategies.
As Chairman of Microsoft India between 2004 and 2011, Ravi was instrumental in creating Microsoft India’s Project Shiksha, a computer literacy program which has so far trained over 35 million school children in India.
Ravi has a BS in engineering from IIT Bombay, an MS from Purdue University, and a MBA from Harvard Business School where he was a Baker Scholar. He is a recipient of the Indian Institute of Technology Bombay’s Distinguished Alumnus Award and Purdue University's Distinguished Engineering Alumnus Award.
RAMESH HARIHARAN, Ph.D
Co-founder and Chief Technology Officer
Dr. Ramesh Hariharan is an academic entrepreneur responsible for the software based technology development and implementation at Strand Life Sciences® (Strand). He is also the chief architect for all of Strand's products, including the award winning AVADIS® platform. He is a recipient of the TR100 Award (2002) of Young Innovators by MIT's Technology Review Magazine and in 2003 received the Global Indus Technovator Award from MIT, instituted to recognize the top 20 Indian technology innovators worldwide. Ramesh is an IIT - Delhi Computer Science alumnus, has a Ph.D. in Computer Science from the Courant Institute of Mathematical Science, New York University and a postdoctoral degree in Computer Science from the Max Planck Institute, Saarbrücken, Germany. His research interests are in sequence analysis, string algorithms, computational biology, computational geometry and foundations of computing.
Managing Director, Biomark Capital LLC
Douglas Lind joined Biomark Capital in November 2013. Previously he served as Managing Director at Burrill & Company and GBP Capital, a Greenwich, Connecticut-based healthcare venture firm. He has more than 20 years experience in the life sciences industry, ranging from the practice of clinical medicine to work as a top tier Wall Street equity research analyst and venture capitalist. Throughout his career he has focused on identifying promising disruptive technologies and visionary leadership that offer high value solutions to pressing medical needs. He served as senior biotechnology equity research analyst at Morgan Stanley from 1997 through 2002 and at PaineWebber from 1995 to 1997. His coverage of large and small capitalization biotechnology companies included Amgen, Biogen, Celera (acquired by Quest Diagnostics), Centocor (acquired by Johnson & Johnson), Chiron (acquired by Novartis), IDEC Pharmaceuticals (acquired by Biogen), ImClone (acquired by Bristol-Myers Squibb), MedImmune (acquired by AstraZeneca), Agouron (acquired by Warner Lambert), Axys Pharmaceuticals (acquired by Celera) and Millenium Pharmaceuticals (acquired by Takeda Pharmaceuticals).
Dr. Lind is a graduate of the University of Iowa College of Medicine. He served as an attending physician at St. Elizabeth's Hospital in Boston, a major teaching affiliate of Tufts University School of Medicine, where he completed residency training in internal medicine. He currently serves on the board of directors of Lentigen, MabVax, TMune, HyperMed Imaging, and Spectral Image.
Managing Partner, Biomark Capital LLC
David Wetherell has spent 20 years as a CEO in high-tech, as well as 17 years in venture capital, the last seven of which have been dedicated to biotech and life sciences. From 1986 to 2006, he served as both CEO and, later, chairman of CMGI, where he helped build the company from $3 million in annual revenues to more than $1 billion and started the first venture capital firm focused on the Internet, @Ventures. In 2003, due to the mapping of the human genome and demographic trends, Wetherell turned his attention to the life sciences.
In 2005, he started GBP Capital, a venture capital company focused exclusively on leading edge life sciences. Wetherell has received numerous awards, including Ernst & Young's New England Entrepreneur of the Year in 2000 and recognition as one of Money Magazine's Top 25 investors. He obtained his B.A. in Mathematics from Ohio Wesleyan University and an honorary doctorate from Bryant University. He currently serves as chairman of Lentigen and sits on the boards of numerous other companies, including HyperMed, Quintess, and Whiteglove Health.